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avirulent, i.e., the strain was unable to make succinyl-CoA,
which in addition to being converted to succinate in the TCA
cycle is required for the biosynthesis of diaminopimelate, a
precursor for the synthesis of lysine, methionine, and peptidoglycan (4, 5, 10, 11, 19). However, it was surprising that the
SR-11 ⌬sdhCDA mutant was less attenuated than the SR-11
⌬mdh mutant, since the conversion of succinate to fumarate
(sdhCDAB) precedes the conversion of malate to oxaloacetate
(mdh) in the TCA cycle. One explanation as to why the SR-11
⌬sdhCDA mutant was less attenuated than the SR-11 ⌬mdh
mutant is the possibility that endogenous fumarate reductase,
which is known to be able to run in the opposite direction, i.e.,
converting succinate to fumarate (6, 13), may be able to substitute for succinate dehydrogenase in SR-11 in vivo and
thereby lessen the effect of the ⌬sdhCDA mutation. Indeed, in
the present study, we show that an SR-11 ⌬frdABCD ⌬sdhCDA
double mutant is both avirulent and immunogenic in BALB/c
mice. Therefore, the data presented suggest that the conversion of succinate to fumarate plays a key role in serovar Typhimurium virulence and raises the possibility that S. enterica
⌬frdABCD ⌬sdhCDA double mutants and ⌬frdABCD ⌬sdhCDA double mutants of other intracellular bacterial pathogens
with complete TCA cycles may prove to be effective live vaccine strains for animals and humans.

Recently, it was reported that the tricarboxylic acid (TCA)
cycle (Fig. 1) operates as a full cycle during infection of
BALB/c mice with Salmonella enterica serovar Typhimurium
strain SR-11 (hereafter called SR-11). Although a complete
TCA cycle appeared to be required for full SR-11 virulence,
the deletion of different TCA cycle genes resulted in different
levels of attenuation (28). We found that an SR-11 ⌬sucAB
mutant, unable to convert ␣-ketoglutarate to succinyl coenzyme A (succinyl-CoA) via the 2-oxoglutarate dehydrogenase
complex (7, 22), was avirulent; that an SR-11 ⌬mdh mutant,
unable to convert malate to oxaloacetate via malate dehydrogenase (7, 30), was highly attenuated; that an SR-11 ⌬sucCD
mutant, unable to generate succinate from succinyl-CoA via
succinyl-CoA synthetase (3, 7), was moderately attenuated;
and that an SR-11 ⌬sdhCDA mutant, unable to generate fumarate from succinate via succinate dehydrogenase (7, 23),
was slightly attenuated. Mutants defective in the ability to run
in the reductive branch of the TCA cycle, i.e., an SR-11 ⌬aspA
mutant (aspartase) unable to convert aspartate to fumarate (7,
27) and an SR-11 ⌬frdABCD mutant (fumarate reductase)
unable to convert fumarate to succinate (6, 7), were fully virulent (28).
It was not surprising that that the SR-11 ⌬sucAB mutant was
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MATERIALS AND METHODS
Bacterial strains, plasmids, and growth media. The bacterial strains and
plasmids used in this study are listed in Table 1. LB broth, Lennox (Difco
Laboratories, Detroit, MI); LB agar, Lennox (Difco); and MacConkey agar
(Difco) were prepared according to package instructions. Liquid M9 minimal
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Previously we showed that the tricarboxylic acid (TCA) cycle operates as a full cycle during Salmonella
enterica serovar Typhimurium SR-11 peroral infection of BALB/c mice (M. Tchawa Yimga et al., Infect. Immun.
74:1130–1140, 2006). The evidence was that a ⌬sucCD mutant (succinyl coenzyme A [succinyl-CoA] synthetase), which prevents the conversion of succinyl-CoA to succinate, and a ⌬sdhCDA mutant (succinate
dehydrogenase), which blocks the conversion of succinate to fumarate, were both attenuated, whereas an SR-11
⌬aspA mutant (aspartase) and an SR-11 ⌬frdABCD mutant (fumarate reductase), deficient in the ability to run
the reductive branch of the TCA cycle, were fully virulent. In the present study, evidence is presented that a
serovar Typhimurium SR-11 ⌬frdABCD ⌬sdhCDA double mutant is avirulent in BALB/c mice and protective
against subsequent infection with the virulent serovar Typhimurium SR-11 wild-type strain via the peroral
route and is highly attenuated via the intraperitoneal route. These results suggest that fumarate reductase,
which normally runs in the reductive pathway in the opposite direction of succinate dehydrogenase, can replace
it during infection by running in the same direction as succinate dehydrogenase in order to run a full TCA cycle
in an SR-11 ⌬sdhCDA mutant. The data also suggest that the conversion of succinate to fumarate plays a key
role in serovar Typhimurium virulence. Moreover, the data raise the possibility that S. enterica ⌬frdABCD
⌬sdhCDA double mutants and ⌬frdABCD ⌬sdhCDA double mutants of other intracellular bacterial pathogens
with complete TCA cycles may prove to be effective live vaccine strains for animals and humans.
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salts medium (20) was supplemented either with reagent-grade glucose (0.2%,
wt/wt) or sodium succinate (0.4%, wt/wt) as the sole sources of carbon and
energy. When necessary, the pH was adjusted to 7.2. SOC medium was prepared
as described by Datsenko and Wanner (9). Agar plates were supplemented with
nalidixic acid (50 g/ml) and/or chloramphenicol (30 g/ml), as appropriate.

Construction and characterization of SR-11 strains. The SR-11 ⌬frdABCD
⌬sdhCDA::cat mutant was constructed from the SR-11 ⌬frdABCD mutant by
deletion mutagenesis using a chloramphenicol cassette as described by Datsenko
and Wanner (9). The primers used previously to create the SR-11 ⌬sdhCDA::cat
mutant (28) were used to construct the double mutant. The “restored” SR-11
⌬frdABCD mutant (wild-type sdhCDA) was constructed by replacing the
⌬sdhCDA::cat sequence in the SR-11 ⌬frdABCD ⌬sdhCDA::cat mutant with the
SR-11 wild-type sequence using the method described by Datsenko and Wanner
(9). A “restored” SR-11 ⌬frdABCD mutant was selected after plating transformants on M9 minimal agar plates containing sodium succinate (0.4%, wt/wt) as
the sole carbon and energy source. As expected, the “restored” SR-11 ⌬frdABCD
mutant was chloramphenicol sensitive and grew at the same rate as the original
SR-11 ⌬frdABCD mutant in M9 minimal medium containing succinate (0.6%,
wt/wt) as the sole carbon and energy source. The primers used to amplify the
wild-type SR-11 sdhCDA sequence used for transformation were as follows:
forward, 5⬘-GCGTACAGGTAGATTCACCTCTG-3⬘ (5⬘ end of the primer begins 68 base pairs upstream of the ATG start codon of the sdhC gene); reverse,
5⬘-GGAACTGCCACATTTCCATGTC-3⬘ (5⬘ end of the primer begins 753 base
pairs downstream of the ATG start codon of the sdhA gene). Constructs were
verified by PCR and sequencing. The primers used for sequencing were the
forward and reverse primers listed previously. The primers were designed by
referring to the complete genome of Salmonella enterica serovar Typhimurium
LT2 (18). When appropriate, the chloramphenicol cassette was removed from
the strains as described by Datsenko and Wanner (9). For sequencing, PCR
products were purified with a Qiaquick PCR purification kit (Qiagen, MD) by
following the manufacturer’s instructions. Each sequencing mixture contained
between 50 and 150 ng of PCR product, 1.6 pmol of primer, and 8.0 l of Quick
Start dye terminator cycle sequencing master mix (Beckman Coulter, Fullerton,
CA). The thermal cycling program consisted of 30 cycles of denaturation at 96°C
for 20 s, annealing at 50°C for 20 s, and elongation at 60°C for 4 min. After the
completion of the cycle sequencing, the samples were purified by ethanol precipitation and separated by polyacrylamide gel electrophoresis on a CEQ 8000
genetic analysis system (Beckman Coulter).
Growth on glucose and sodium succinate in M9 minimal medium. To test the
rates of growth of wild-type SR-11 and SR-11 ⌬frdABCD ⌬sdhCDA::cat in M9
minimal medium containing glucose as the sole carbon and energy source (20),
overnight cultures grown in LB broth were washed twice in M9 minimal medium
(no carbon source), 100 l of the washed cultures was transferred to 10 ml of M9
minimal medium containing reagent-grade glucose (0.4%, wt/wt) as the sole
carbon and energy source, and the cultures were incubated at 37°C with shaking
in 125-ml tissue culture bottles overnight. The next morning, overnight cultures
were diluted to an A600 of about 0.1 in 20 ml of fresh M9 minimal medium
containing reagent-grade glucose (0.4%, wt/wt) as the sole carbon and energy
source, and the cultures were incubated at 37°C with shaking in 125-ml tissue
culture bottles. A600 measurements were taken at 60-min intervals. The same
protocol used for growth on glucose was used for testing the rates of growth of
the original SR-11 ⌬frdABCD mutant and the “restored” SR-11 ⌬frdABCD

TABLE 1. Strains and plasmids of serovar Typhimurium used in this study
Strain or plasmid

Strains
Wild-type SR-11
SR-11 ⌬frdABCD
SR-11 ⌬sdhCDA
SR-11 ⌬frdABCD
⌬sdhCDA::cat
“Restored” SR-11
⌬frdABCD
Plasmids
pKD3
pKD46
pCP20

Relevant characteristic(s)

gyr-1816
gyr-1816 ⌬frdABCD
gyr-1816 ⌬sdhCDA
gyr-1816 ⌬frdABCD ⌬sdhCDA::cat
gyr-1816 ⌬frdABCD

Template plasmid containing chloramphenicol resistance
cassette flanked by FLP recombinase target sites; bla cat
Temperature-sensitive plasmid containing arabinoseinducible phage  red recombinase gene for linear DNA
exchange; bla
Temperature-sensitive plasmid containing FLP recombinase
gene for removal of antibiotic resistance cassettes; bla cat

Defect(s)

None
Fumarate reductase
Succinate dehydrogenase
Fumarate reductase and
succinate dehydrogenase
Fumarate reductase

Source or
reference

8
28
28
This study
This study

9
9
9
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FIG. 1. Embden-Meyerhoff pathway, gluconeogenic pathway, and
TCA cycle. Arrows indicate the physiological directions of the reactions. Genes encoding the enzymes for each reaction are listed beside
each reaction.
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RESULTS
An SR-11 ⌬frdABCD ⌬sdhCDA::cat double mutant is avirulent (108 CFU/mouse, peroral route). BALB/c mice were infected orally with 108 CFU (i.e., about 103 times the wild-type
50% lethal dose [LD50]) (8) of either wild-type SR-11, SR-11
⌬sdhCDA, SR-11 ⌬frdABCD, or SR-11 ⌬frdABCD ⌬sdhCDA::
cat. As reported previously, the SR-11 ⌬sdhCDA mutant
was slightly attenuated (P ⫽ 0.0068) (Fig. 2A) and the SR-11
⌬frdABCD mutant was fully virulent (P ⫽ 0.94) (Fig. 2A). In

FIG. 2. Survival of BALB/c mice infected orally with 108 CFU of
wild-type SR-11 (䉬), SR-11 ⌬frdABCD (䡺), or SR-11 ⌬sdhCDA (Œ)
(A); either wild-type SR-11 (䉬) or SR-11 ⌬frdABCD ⌬sdhCDA::cat
(f) (B); and either wild-type SR-11 (䉬) or the “restored” SR-11
⌬frdABCD mutant (f) (C).

contrast, the SR-11 ⌬frdABCD ⌬sdhCDA::cat double mutant
was avirulent (P ⬍0.0001) (Fig. 2B). The SR-11 ⌬frdABCD
⌬sdhCDA::cat double mutant has a chloramphenicol cassette
replacing the wild-type sdhCDA genes (Table 1). When the
chloramphenicol cassette was removed as described by Datsenko and Wanner (9), the strain remained totally avirulent
(data not shown), proving that the chloramphenicol cassette
was not responsible for the avirulence of the SR-11 ⌬frdABCD
⌬sdhCDA::cat double mutant.
The SR-11 ⌬frdABCD ⌬sdhCDA::cat double mutant was
constructed by deleting sdhCDA from the SR-11 ⌬frdABCD
mutant. To prove conclusively that the ⌬sdhCDA deletion was
responsible for the avirulence of the SR-11 ⌬frdABCD
⌬sdhCDA::cat double mutant, the wild-type sdhCDA genes
were reinserted into the double mutant to regenerate the
SR-11 ⌬frdABCD mutant (see Materials and Methods). The
“restored” SR-11 ⌬frdABCD mutant grew with succinate as
the sole source of carbon and energy at the same rate as the
original SR-11 ⌬frdABCD mutant (not shown) and was fully
virulent (P ⫽ 0.89) (Fig. 2C). Collectively, these data suggest
that in BALB/c mice, fumarate reductase can take over for
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mutant on M9 minimal medium containing sodium succinate (0.6%, wt/wt) as the
sole carbon and energy source. In all growth experiments, growth was monitored
spectrophotometrically (A600) using a Pharmacia Biotech Ultrospec 2000 UV/
visible-spectrum spectrophotometer.
Virulence assays. Virulence assays were carried out as described previously
(1). Briefly, 4-week-old, 13- to 15-g female BALB/c mice (Charles River Laboratories, Wilmington, MA) were housed at no more than four per cage, with pine
shavings as bedding. Prior to infection, the mice were starved for food and water
for 4 h. Following starvation, 50 l of 10% sodium bicarbonate was administered
orally to each mouse in order to neutralize gastric acidity, and 30 min later, 108
CFU of a specific strain in 20 l of phosphate-buffered saline (pH 7.4) containing
0.1% gelatin was administered orally to each of four mice. For virulence assays
via the intraperitoneal (i.p.) route, 103 CFU or 104 CFU of a specific strain in 100
l of phosphate-buffered saline (pH 7.4) containing 0.1% gelatin was injected by
sterile syringe into each of four mice. The number of CFU administered to mice was
measured by diluting and then plating bacterial suspensions onto MacConkey agar
containing nalidixic acid (50 g/ml). After infection, food and water were restored to the mice and the mice were inspected four times daily for obvious signs
of illness (ruffled fur, crusted and closed eyes, loss of appetite, crouched posture
and shivering) and death.
Definition of fully virulent, attenuated, and avirulent. A set of four mice were
infected orally with 108 CFU of a specific SR-11 deletion mutant, and an additional four mice were infected orally with 108 CFU of wild-type SR-11 in each
virulence experiment. The data presented here are composites of at least two
identical but independent experiments (eight mice). When mice infected with a
specific mutant remain healthy, i.e., show no signs of illness throughout the
30-day duration of the experiment, the mutant is considered to be avirulent. The
term “fully virulent” is used when mice infected with a particular mutant show
the same signs of illness as mice infected with the wild-type SR-11 strain and the
survival curve is not statistically different from that of mice infected with the
wild-type SR-11 strain. The term “attenuated” is used when the mice infected
with a particular mutant show signs of illness but the survival curve is statistically
different from that of mice infected with the wild-type SR-11 strain and death is
delayed. The extent to which death is delayed is denoted by the term “slightly
attenuated,” “attenuated,” or “highly attenuated,” conditions which are clarified
by results shown in the figures.
Protection assays. Thirty days after peroral infection with SR-11 ⌬frdABCD
⌬sdhCDA::cat, which is sufficient time for mice to mount an intestinal mucosal
immunological response and a systemic immunological response, BALB/c mice
were challenged perorally with 108 CFU of wild-type SR-11, as described above.
In each experiment, an age-matched set of sham-vaccinated BALB/c mice were
also challenged with 108 CFU of wild-type SR-11. Mice were then observed each
day in the morning and 8 hours later for obvious signs of illness (ruffled fur,
crusted and closed eyes, loss of appetite, crouched posture and shivering) and
death.
CFU in Peyer’s patches, liver, and spleen. Mice were euthanized by CO2
asphyxiation. Peyer’s patches (four per mouse) were removed from the ileum and
terminal ileum as described by Curtiss and Kelly (8) and homogenized. Homogenates were diluted and plated on McConkey agar containing nalidixic acid (50
g per ml) to determine the number of CFU and were tested for protein
concentration by the Bradford assay (3a). Data are presented as log10 number of
CFU/mg of protein. Livers and spleens were removed and homogenized in Luria
broth. Homogenates (0.1 g per ml, wt/wt) were diluted and plated on McConkey
agar containing nalidixic acid (50 g per ml) to determine the number of CFU
per organ. Plates were incubated at 37°C for at least 18 h prior to counting the
CFU. Data are presented as log10 number of CFU/organ.
Statistics. Mouse survival curves were compared for differences using the
Kaplan-Meier method (MedCalc Software, Belgium). Survival curves were considered to be different if the P value was less than 0.05.
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FIG. 3. Survival of BALB/c mice initially sham infected orally and infected 30 days later with 108 CFU of wild-type SR-11 (䉬) or initially
infected orally with 108 CFU of SR-11 ⌬frdABCD ⌬sdhCDA::cat and infected 30 days later with 108 CFU of wild-type SR-11 (f).

FIG. 4. Recovery of wild-type SR-11 (䉬) from Peyer’s patches of
BALB/c mice orally infected with 108 CFU of the strain, and recovery
of SR-11 ⌬frdABCD ⌬sdhCDA::cat from Peyer’s patches of BALB/c
mice orally infected with 108 CFU of the strain (f). Each data point
for days 1 to 4 represents the log10 number of CFU per mg of Peyer’s
patch protein (mean ⫾ the standard error) for four animals. The day
6 data points are derived from two animals.

SR-11 strain throughout the 6-day duration of the experiment
(not shown).
The SR-11 ⌬frdABCD ⌬sdhCDA::cat double mutant does not
grow well in the liver and spleen relative to the growth of
wild-type SR-11. As serovar Typhimurium grows in Peyer’s
patches, it simultaneously disseminates systemically in macrophages to the liver and spleen, where it continues to grow (25,
26). Experiments were therefore performed to determine the
rate of appearance of SR-11 ⌬frdABCD ⌬sdhCDA::cat in the
liver and spleen relative to that of wild-type SR-11. As shown
in Fig. 5A and B, the SR-11 wild-type strain appeared in the
liver and spleen a day before SR-11 ⌬frdABCD ⌬sdhCDA::cat
and by day 6 was, in numbers, about 5 orders of magnitude
higher than in the liver (Fig. 5A) and about 6 orders of magnitude higher than in the spleen (Fig. 5B). The same experiment was performed using the moderately attenuated SR-11
⌬sucCD mutant (28). The numbers of the SR-11 ⌬sucCD mutant in the liver and spleen were essentially identical to those of
the wild-type SR-11 strain throughout the 6-day duration of
the experiment (not shown). While these data tell us nothing
about why the SR-11 ⌬sucCD mutant is moderately attenuated, they do suggest that the moderate attenuation has nothing to do with early systemic dissemination.
The SR-11 ⌬frdABCD ⌬sdhCDA::cat double mutant is highly
attenuated via the i.p. route. As stated above, when mice are
infected via the oral route, serovar Typhimurium initially enters M cells, then enters lymphoid cells of the Peyer’s patches
(14, 15), and finally resides and grows in macrophages in the
liver and spleen (16, 25). In contrast, infection via the i.p. route
results exclusively in systemic exposure in macrophages. An i.p.
infection with as few as 40 to 50 CFU of wild-type SR-11 can
be fatal to BALB/c mice (8, 29). Of the eight BALB/c mice
infected i.p. with 103 CFU of the SR-11 ⌬frdABCD ⌬sdhCDA
double mutant (about 25 times the wild-type LD50 [8]), six
mice survived the 30 days of the experiment (Fig. 6A), whereas
of eight BALB/c mice infected with 104 CFU of the SR-11
⌬frdABCD ⌬sdhCDA::cat double mutant (about 250 times the
wild-type LD50 [8]), only three survived the entire 30 days (Fig.
6B). However, of 16 BALB/c mice infected i.p. with the SR-11
wild-type strain (8 mice with 103 CFU and 8 mice with 104
CFU), all 16 were dead within 5 days postinfection (Fig. 6A
and B). Of the surviving mice infected with the SR-11 ⌬frdABCD
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succinate dehydrogenase in the SR-11 ⌬sdhCDA mutant to
convert succinate to fumarate and thereby run a full TCA cycle
with only a minor reduction in virulence. In addition, the data
suggest that the conversion of succinate to fumarate is required
for SR-11 virulence in BALB/c mice.
The SR-11 ⌬frdABCD ⌬sdhCDA::cat double mutant is immunogenic. Not all avirulent serovar Typhimurium mutants
protect BALB/c mice against subsequent infection with the
wild-type strain. For example, the SR-11 ⌬sucAB mutant is
avirulent (28), but when mice were orally challenged with 108
CFU of the wild-type SR-11 strain 30 days after being fed 108
CFU of the SR-11 ⌬sucAB mutant, all of the mice died within
12 days (M. Tchawa Yimga, unpublished data). In contrast,
when BALB/c mice originally fed 108 CFU of the SR-11
⌬frdABCD ⌬sdhCDA::cat mutant were orally challenged with
108 CFU of the wild-type SR-11 strain 30 days later, they never
appeared ill and remained healthy throughout the ensuing 30
days postchallenge (Fig. 3). However, sham-infected mice
orally challenged with 108 CFU of the wild-type SR-11 strain
30 days after sham infection all died within 10 days (Fig. 3).
Therefore, the SR-11 ⌬frdABCD ⌬sdhCDA::cat double mutant
was fully protective against a challenge with wild-type SR-11
(P ⫽ 0.0001).
The SR-11 ⌬frdABCD ⌬sdhCDA::cat double mutant is found
in numbers equal to those of wild-type SR-11 in Peyer’s
patches. After ingestion, serovar Typhimurium survives passage through the acidic environment of the stomach and
reaches the terminal ileum, where it invades M cells in the
Peyer’s patches (15). Serovar Typhimurium then gains access
to both adjacent enterocytes and underlying lymphoid cells in
the mesenteric lymph follicles of the Peyer’s patches (15, 16).
Since growth initially takes place in the Peyer’s patches (14)
and the SR-11 ⌬frdABCD ⌬sdhCDA::cat double mutant was
avirulent via the peroral route, experiments were performed to
determine whether it had a defect in growth or survival in
Peyer’s patches. As shown in Fig. 4, the numbers of CFU of the
SR-11 ⌬frdABCD ⌬sdhCDA::cat double mutant in Peyer’s
patches were essentially identical to those of the wild-type
SR-11 strain throughout the 6-day duration of the experiment.
The same experiment was performed using the SR-11 ⌬sucCD
mutant, which is moderately attenuated; i.e., the death of
BALB/c mice fed the SR-11 ⌬sucCD mutant is delayed 10 days
relative to that of BALB/c mice fed wild-type SR-11 (28). The
numbers of CFU of the SR-11 ⌬sucCD mutant in Peyer’s
patches were essentially identical to those of the wild-type
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⌬sdhCDA::cat double mutant, all had ruffled fur for about 3
weeks, but by the end of the experiment, they looked completely healthy. Therefore, although not completely avirulent
via the i.p. route, the SR-11 ⌬frdABCD ⌬sdhCDA::cat double
mutant was highly attenuated when mice were inoculated with
either 103 CFU (P ⫽ 0.0001) or 104 CFU (P ⬍ 0.0001).
SR-11 ⌬frdABCD ⌬sdhCDA::cat grows normally in M9
minimal medium containing glucose. The fact that the SR-11
⌬frdABCD ⌬sdhCDA::cat double mutant is avirulent supports
the previous report (28) suggesting that full SR-11 virulence
requires the TCA cycle to operate as a complete cycle. It might
be argued, however, that the SR-11 ⌬frdABCD ⌬sdhCDA::cat
double mutant has a general growth defect that would be
observed even if the TCA cycle were not running as a complete
cycle. It was therefore of interest to examine the growth rates
of wild-type SR-11 and the SR-11 ⌬frdABCD ⌬sdhCDA::cat
double mutant during aerobic growth with glucose (0.4%, wt/
wt) as the sole source of carbon and energy, a condition in
which the TCA cycle operates in the oxidative- and reductivebranch mode (7, 21), requiring neither succinate dehydrogenase nor ␣-ketoglutarate dehydrogenase (5, 7). Each strain
grew identically, with generation times of about 70 min (not
shown). Therefore, the avirulence of the SR-11 ⌬frdABCD
⌬sdhCDA::cat double mutant does not appear to be due to a
general growth defect but does appear to be due to the inability
of the mutant to run a full TCA cycle.

FIG. 6. Survival of BALB/c mice infected intraperitoneally with 103
CFU (A) or 104 CFU (B) of wild-type SR-11 (䉬) or SR-11 ⌬frdABCD
⌬sdhCDA::cat (f).

DISCUSSION
In a previous report, we showed that an SR-11 ⌬frdABCD
mutant, unable to make fumarate reductase, was completely
virulent in BALB/c mice and that an SR-11 ⌬sdhCDA mutant,
unable to make succinate dehydrogenase, was only slightly
attenuated (28). In the present study, evidence is presented
that an SR-11 ⌬frdABCD ⌬sdhCDA::cat double mutant is avirulent. Fumarate reductase and succinate dehydrogenase are
physiologically reversible isoenzymes which are induced under
anaerobic and aerobic conditions, respectively (6, 13). Our
data suggest that fumarate reductase, which normally runs in
the reductive pathway in the opposite direction of succinate
dehydrogenase for branched TCA cycle operation, takes over
for succinate dehydrogenase in the SR-11 ⌬sdhCDA mutant
during infection to run a full TCA cycle with only a slight
reduction in virulence (Fig. 2A). In addition, it appears that
the conversion of succinate to fumarate is key to the virulence
of serovar Typhimurium.
At the present time, we do not know why blocking the
conversion of succinate to fumarate results in avirulence but
blocking the conversion of succinyl-CoA to succinate, which
precedes the conversion of succinate to fumarate in the TCA
cycle (Fig. 1), results in only moderate attenuation (28). We do
know, however, that an SR-11 ⌬mdh mutant, which is unable
to make malate dehydrogenase and therefore cannot convert
malate to oxaloacetate (30), is highly attenuated (28) and that
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FIG. 5. Recovery of wild-type SR-11 (䉬) from the livers (A) and
spleens (B) of BALB/c mice orally infected with 108 CFU of the strain
and recovery of SR-11 ⌬frdABCD ⌬sdhCDA::cat (f) from the livers
(A) and spleens (B) of BALB/c mice orally infected with 108 CFU of
the strain. Each data point represents the log10 mean number of CFU
per organ (mean ⫾ the standard error) for four animals.
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an SR-11 ⌬sfcA ⌬maeB mutant, unable to make the “malic”
enzymes for the conversion of malate to pyruvate (2, 17), is
attenuated (28). Thus, a continuous supply of malate is required not only for the generation of oxaloacetate but also for
the generation of pyruvate (Fig. 1). Removing malate from the
TCA cycle to make pyruvate requires that malate be replenished to keep a full TCA cycle operative. Since replenishment
appears to be independent of the conversion of phosphoenolpyruvate to oxaloacetate (see Fig. 1), i.e., an SR-11 ⌬ppc mutant has been shown to be fully virulent (28), it may be that
malate replenishment comes via succinate present in mouse
tissue or via ornithine and arginine present in mouse tissue that
may be converted to succinate (24). If so, and if neither fumarate nor malate in tissue is available to replenish malate in the
SR-11 TCA cycle, succinate conversion to fumarate and then
to malate would be key to SR-11 virulence. This scenario also
explains why the conversion of succinyl-CoA to succinate is not
as key to virulence as the conversion of succinate to fumarate;
i.e., in an SR-11 ⌬sucCD mutant, the mouse tissue succinate
would still allow some replenishment of malate in the TCA
cycle. If this hypothesis is true, it would be expected that an
SR-11 ⌬fumA ⌬fumB ⌬fumC triple mutant, unable to convert
fumarate to malate either aerobically or anaerobically (12),
and an SR-11 ⌬sfcA ⌬maeB ⌬mdh triple mutant, unable to
generate either pyruvate or oxalacetate from malate (Fig. 1),
would both be avirulent. Experiments designed to test this
hypothesis are currently under way.
When fed to BALB/c mice orally, the SR-11 ⌬frdABCD
⌬sdhCDA::cat double mutant appears to have no growth defect
in Peyer’s patches (Fig. 4) but is delayed in reaching the liver
and spleen and does not accumulate in these organs to nearly
the same extent as does wild-type SR-11 (Fig. 5A and B).
In fact, the data presented here for the SR-11 ⌬frdABCD
⌬sdhCDA double mutant are reminiscent of those reported for
an SR-11 ⌬cya ⌬crp mutant that was unable to make both
adenyl cyclase and the cAMP receptor protein (8); i.e., in both
cases, the strains are avirulent via the peroral route, have no
apparent defect in invading or persisting in Peyer’s patches, are
impaired in their ability to reach and grow in the liver and
spleen, are severely attenuated but not avirulent via the i.p.
route of infection, and are immunogenic.
While the reason that the SR-11 ⌬frdABCD ⌬sdhCDA::cat
double mutant is avirulent is not fully explained by our experiments, it is clear that this strain effectively protects BALB/c
mice against subsequent infection with wild-type SR-11. In this
context, it will be of great interest to determine whether
⌬frdABCD ⌬sdhCDA mutants of intracellular bacterial pathogens other than S. enterica serovar Typhimurium that cannot
convert succinate to fumarate are avirulent and whether they
can also protect animals against infection by their virulent
parents. If so, it may be that S. enterica ⌬frdABCD ⌬sdhCDA
double mutants and ⌬frdABCD ⌬sdhCDA double mutants of
other intracellular bacterial pathogens with complete TCA cycles can serve as effective live vaccine strains for both animals
and humans. Moreover, serovar Typhimurium ⌬frdABCD
⌬sdhCDA double mutants might be effective as vehicles for
genes that express virulence antigens of other pathogens to
induce protective immunity against those pathogens.
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